Learn about the world’s most advanced ex vivo immuno-oncology models.
Innovation milestone is a message of authentic hope for local cancer patients By Matthew Gevaert, Ph.D., and W. Jeffrey Edenfield, MD Cancer innovation and hiking the Appalachian Trail have a few things in common. Neither happens overnight; the AT typically takes five to seven months, and meaningful innovation in cancer research can take five toRead More
Staff Report – 12.14.17 The Greenville Hospital System Cancer Institute and Greenville-based KIYATEC have partnered to provide cancer patients with the diagnostic testing they need to make informed health decisions. The first of these tests to be available is one that can indicate ovarian cancer patients’ future response to chemotherapy before undergoing treatment with up to 93% accuracy, accordingRead More
Three KIYATEC abstracts accepted for poster presentations during 2017 AACR Conference in Washington D.C. KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference. GREENVILLE, SC, March 21, 2017– KIYATEC Inc. is pleased to announce that three abstracts haveRead More
KIYATEC AND MAYO CLINIC COLLABORATE TO FIGHT OVARIAN CANCER Collaboration aims to validate the accuracy ex vivo 3D (EV3D) cell culture predictions against ovarian cancer patient outcomes Greenville, S.C. | June 16, 2016 07:00 EDT – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced a collaboration with Mayo Clinic toRead More